Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
NCT06234605 trial: what clinicians have said so far
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
- NCT06234605 ↗
- Recruiting
- HiberCell, Inc.
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT06234605 (HC-7366 plus belzutifan; HC-7366 in locally advanced or metastatic renal cell carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT06234605 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 2 posts on X, typically up to 9 once built | |
| 1 YouTube video, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC- 7366 in Combination With Belzutifan (WELIREG™) in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- Renal Cell Carcinoma
- Interventions
- HC-7366; Belzutifan
- Arms
- Monotherapy · Experimental
- Combination · Experimental
- Enrollment
- 80 (estimated)
- Primary outcomes
- Determination of MTD and RP2D (combination cohorts only)
- Sponsor
- HiberCell, Inc. with Merck Sharp & Dohme LLC
- Start
- Apr 29, 2024
- Primary completion
- Nov 2026 (estimated)
- Results posted
- No
- Registry record
- NCT06234605 · updated Oct 2, 2026